← Shaanxi Kanghui Pharm overview

Shaanxi Kanghui Pharm vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shaanxi Kanghui Pharm Co Ltd (603139.CG)

Q3 2026
▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

  • New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.

    These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.

  • Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.

    This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.

  • First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.

    The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.

  • Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.

    This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

August 2026
▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

  • New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.

    These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.

  • Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.

    This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.

  • First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.

    The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.

  • Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.

    This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

Latest
▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

  • New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.

    These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.

  • Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.

    This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.

  • First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.

    The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.

  • Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.

    This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.